Pfizer nelle notizie
Sviluppo di terapie sanitarie innovative
Tamtam ha trovato 20 articoli recenti su Pfizer.
- No, Pfizer CEO did not say it planned to halve the world’s population
- Should FDA Approval of Updated COVID Vaccine for Vulnerable Groups Prompt a Closer Look at Pfizer (PFE)?
- Mixed options sentiment in Pfizer with shares up 0.63%
- Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
- Florida Attorney General James Uthmeier sues Pfizer for misleading vaccination claims
- Pfizer Declares Fourth-Quarter 2026 Dividend
- Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
- Is Pfizer (PFE) a Good or Bad Investment at Today’s Price?
- Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
- Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
- Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
- Pfizer Inc. stock underperforms Friday when compared to competitors
- Pfizer says phase 3 data buoys Litfulo as a vitiligo treatment
- Pfizer’s Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Here’s What It Means for the Stock
- Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- Pfizer’s Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Here’s What It Means for the Stock
- Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
- Pfizer touts 'dermatology momentum' as it paints fuller picture of Litfulo's vitiligo potential
- How Has Pfizer’s Story Changed?
- Uthmeier alleges Pfizer misled Florida about its COVID vaccine’s safety
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Pfizer?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili